Oligonucleotide Manufacturing Market: Global, Annual Capacity |
Posted: June 23, 2020 |
The global, annual manufacturing capacity for oligonucleotides is primarily driven by mid- to large-sized contract / custom service providers. The current, annual capacity is primarily driven by players operating at the commercial scale, which represent 96% of the total manufacturing capacity, while the remaining capacity is installed in companies operating at preclinical / clinical scales.
In addition, around 74% of the capacity belongs to large-scale manufacturers of oligonucleotides. This can also be attributed to the fact that large companies usually have multiple facilities at different locations and the aforementioned distribution takes into account the annual capacity at all facilities.
It is worth noting that, at present, 50-60% of the global, annual capacity belongs to large players, such as Agilent Technologies, Ajinomoto Bio-Pharma Services, and Nitto Denko Avecia. Further, mid-sized service providers contribute to around 35-40% of the overall capacity. Recent advancements in therapeutic oligonucleotides have led to an increase in the demand for their APIs. In order to meet this increased demand, we believe that mid-sized and small companies need to expand their current capacities.
Further, majority share (66%) of the overall oligonucleotide manufacturing capacity is installed in facilities located within North America, primarily the US. This can be attributed to the fact that a large number of oligonucleotide manufacturers are based in the US. Further, inherent technical, regulatory and financial superiority of this region are anticipated to be the key drivers that are likely to compel manufacturer to set up their facilities in in this region.
This is followed by the facilities based in Europe, where 26% of the overall capacity is installed. The remaining capacity (8%) is installed in facilities located in Asia-Pacific. It is worth highlighting that companies based in Asia-Pacific are increasingly undertaking various expansion initiatives in order to expand their manufacturing capabilities and catch-up with their competitors based in North America and Europe.
In fact, in an interview with founder and managing director of a small company, he stated that “The growth prospects in this domain seem optimistic. Presently, companies with in-house production facilities lack the necessary capacity to produce advanced oligonucleotide-based products; such operations are likely to be outsourced to service providers with proven expertise.”
Complete report by Roots Analysis: Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Therapeutic Applications, 2020-2030
|
|||||||||||||||||||||||||||||||||||||||||||
|